TL;DR
This paper presents a novel, cost-effective immunoassay system leveraging Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) for enhanced sensitivity and specificity in detecting biomarkers. The system's innovative design, featuring a time-resolved detection module and a novel filter-switching mechanism, addresses limitations of existing high-cost TR-FRET platforms, paving the way for more accessible in vitro diagnostics.
What Problem Does This Paper Address?
Current in vitro diagnostics (IVD) heavily rely on immunoassays, with magnetic particle chemiluminescence being a popular but complex method. These methods can be labor-intensive, require specialized expertise, and are susceptible to issues with magnetic bead performance and separation. While advanced TR-FRET technologies exist, their prohibitive costs and proprietary reagent restrictions limit widespread adoption. This creates a need for a more economical, user-friendly, and high-performance TR-FRET immunoassay system capable of multiplexed detection of critical biomarkers, particularly for inflammatory diseases.
Methods
The core of this work is the development of a TR-FRET immunoassay system that combines TR-FRET principles with time-resolved measurement techniques.
- TR-FRET Principle: The system utilizes donor (Europium cryptate) and acceptor (Cy5) fluorescent probes. When excited, the donor transfers energy to the acceptor via FRET, resulting in a long-lifetime fluorescence emission from the acceptor. This energy transfer is distance-dependent (1-10 nm range), enabling specific detection of analytes.
- Time-Resolved Detection: To overcome background noise from short-lived fluorescence, a time-delayed measurement is employed. A xenon flash lamp serves as the excitation source, and a photomultiplier tube (PMT) acts as the detector. A crucial component is a filter-switching mechanism that allows sequential measurement of donor and acceptor fluorescence. This mechanism uses a stepper motor to precisely switch between filters optimized for the donor (620 nm) and acceptor (665 nm) emission wavelengths.
- Instrument Design: The instrument is modular, comprising a pipetting module, reagent and sample handling, a detection module with temperature control, an electronic control module, and a waste container. The detection module is designed to be light-tight to minimize noise. The control system is built around an STM32F103VCT6 microcontroller, managing the xenon lamp, PMT, and filter switching.
- Reagent Preparation: The paper details the conjugation of antibodies with Eu3+ cryptate and disulfo-Cy5 NHS ester, followed by purification. The antigen detection assay involves mixing samples with these labeled antibodies and measuring FRET signals.
Datasets
The paper does not describe the use of pre-existing datasets for training. Instead, it focuses on the development and validation of a new instrument. The evaluation involves:
- Fluorescent Molecule Linearity: A fluorescent molecule was serially diluted to six concentrations (0.01 nM to 10 nM) to assess the linearity of the instrument's response.
- Biomarker Detection: Standard samples of Procalcitonin (PCT), C-reactive protein (CRP), and Interleukin-6 (IL-6) at various known concentrations were used to evaluate the system's performance for specific analytes.
Key Insights and Ideas
- Cost-Effective TR-FRET: The primary insight is the successful development of a functional TR-FRET immunoassay system that is significantly more affordable than existing commercial options, addressing a major barrier to adoption.
- Integrated Time-Resolved Detection: The novel filter-switching mechanism and the precise timing of excitation and detection are key to achieving high sensitivity by effectively separating the long-lived FRET signal from transient background fluorescence.
- Multiplexed Detection Potential: While the paper focuses on PCT, CRP, and IL-6, the TR-FRET principle and the instrument's design lay the groundwork for multiplexed detection of multiple biomarkers simultaneously.
- No-Wash Advantage: The TR-FRET method inherently eliminates the need for washing steps, simplifying the assay protocol and reducing operational complexity and time.
Key Results
- Counting Module Performance: The self-designed counting module demonstrated excellent precision, with CV values consistently below 0.01%.
- Instrument Noise: Instrument noise at 620 nm and 665 nm was measured at 41.44 and 10.59, respectively.
- Temperature Stability: The detection darkroom maintained excellent temperature stability, with a bias of 0.06 °C and a fluctuation of 0.10 °C at a set point of 37 °C.
- Pipetting Accuracy: The pipetting module showed good accuracy and repeatability, with CV values between ±3% and 5% and bias within ±3% and 5% for volumes ranging from 10 µL to 100 µL.
- Linearity: The instrument exhibited excellent linearity for fluorescent molecules, with linear regression correlation coefficients greater than 0.999 in the 0.01 nM to 10 nM range.
- Biomarker Detection Performance:
- PCT: Linear regression correlation coefficient exceeded 0.999 for concentrations from 0.02 ng/mL to 50 ng/mL, with a limit of quantification (LOQ) of 0.096 ng/mL.
- CRP: Demonstrated excellent linear characteristics with an LOQ of 2.70 ng/mL.
- IL-6: Showed excellent linear characteristics with an LOQ of 2.82 ng/mL.
- Performance Comparison: The self-developed instrument offers comparable quantitative linear ranges for PCT to a Thermo Fisher Scientific instrument but at a significantly lower cost.
Limitations and Future Work
- Limited Biomarker Range (Current): While the system is designed for multiplexing, the current experimental validation focuses on PCT, CRP, and IL-6. The paper mentions SAA as "under development."
- Reagent Specificity: The paper details the construction of labeled antibodies, implying that specific reagents need to be developed for each target analyte.
- Future Work: The authors suggest that the developed system holds promise for advancing immunodiagnostic technology, enhancing the efficiency and effectiveness of disease management. Further development could focus on expanding the range of detectable biomarkers and optimizing assay protocols for clinical applications. The comparison table also hints at potential future work in developing reagents for other analytes like CRP and IL-6.
Summary updated